Abstract
The 90-kD heat shock protein (Hsp90) is an abundant molecular chaperone catalyzing maturation and activation of client proteins. A number of the Hsp90 client proteins are components of cancer cell-associated signaling pathways that ensure unlimited growth of tumors and their resistance to chemotherapy and radiotherapy. Upon inhibition of the Hsp90 chaperone function, such client proteins are destabilized and degraded which disrupts multiple pathways essential for tumor cell survival; hence, pharmacological Hsp90 inhibitors could be applied in anticancer therapy. Several Hsp90-inhibiting compounds are currently tested in preclinical or phase I–III clinical trials as single anticancer agents or in combination with conventional drugs and radiation. The present review summarizes the data characterizing Hsp90 inhibitors as agents that sensitize human tumors to irradiation which may improve the outcome of radiotherapy. We also discuss molecular mechanisms of the Hsp90 inhibition-induced radiosensitization and its selectivity toward cancer cells.
Similar content being viewed by others
References
Stravopodis DJ, Margaritis LH, Voutsinas GE (2007) Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 14:3122–3138
Hwang M, Moretti L, Lu B (2009) Hsp90 inhibitors: multi-target antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem 16:3081–3092
Kamal A, Thao L, Sensintaffar J, Boehm ZL, MF FLC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410
Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 6:103–34
Russel JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003) Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9:3749–3755
Enmon R, Yang W-H, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G (2003) Combination treatment with 17-N-Allylamino-17-Demethoxy Geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 63:8393–8399
Ochel HJ, Gademan G (2006) In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. Anticancer Res 26:2085–2091
Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, Ando K, Okayasu R (2006) Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxy- geldanamycin. Biochem Biophys Res Commun 351:658–663
Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ (2004) Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 10:8077–8084
Dote H, Cerna D, Burgan W, Camphausen K, Tofilon PJ (2005) ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 65:6967–6975
Harashima K, Akimoto T, Nonaka T, Tsuzuki K, Mitsuhashi N, Nakano T (2009) Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell death in a hormone-sensitive prostate cancer cell line trough degradation of the androgen receptor. Int J Radiat Biol 81:63–76
Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY (2009) Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11:109–121
Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984–8995
Dote H, Burgan WE, Camphausen K, Tofilon J (2006) Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res 66:9211–9220
Machida H, Matsumoto Y, Shirai M, Kubota N (2003) Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 79:973–980
Kim WY, Oh SH, Woo JK, Hong WK, Lee HY (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1α. Cancer Res 69:1624–1632
Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L (2008) HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 7:1985–1992
Matsumoto Y, Machida H, Kubota N (2005) Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res (Tokyo) 46:215–221
Kobayashi S, Nantz R, Kitamura T, Higashikubo R, Horikoshi N (2005) Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. Oncogene 24:3011–3019
Mashida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shira M, Kubota N (2005) Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 96:911–917
Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H (2006) P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol 29:1111–1115
Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ, Kim IH, Atadja P, Bernhard EJ (2009) Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol 92:125–132
Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG (2009) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer (in press)
Yi T, Li H, Wang X, Wu Z (2008) Enhancement radiosensitization of breast cancer cells by deguelin. Cancer Biother Radiopharm 23:355–362
Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S (2009) Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 100:334–343
Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6:3312–3318
O’Callaghan-Sunol C, Gabai VL (2007) Involvement of heat shock proteins in protection of tumor cells from genotoxic stresses. In: Calderwood S, Sherman MY, Ciocca DR (eds) Heat shock proteins in cancer, Springer, pp. 169–190
Kabakov A (2007) Heat shock proteins against radiation-induced apoptosis: facts, hypotheses, prospects. In: Corvin A (ed) New developments in cell apoptosis research. Nova Science Publishers, NY, pp. 121–158
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159
Kabakov AE, Makarova YM, Malyutina YV (2008) Radiosensitization of human endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 71:858–865
Daozhen C, Lu L, Min Y, Xinyu J, Ying H (2007) Synthesis of (131)I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin ([(131)I]iodo-17-AAG) and its biodistribution in mice. Cancer Biother Radiopharm 22:607–612
Wenyong T, Lu L, Daozhen C, Weidong Y, Ying H (2009) An experimental study on the antitumor effect of 131I–17-AAG in vitro and in vivo. Ann Nucl Med 23:113–122
Bertram J, Palfner K, Hiddemann W, Kneba M (1996) Increase of P-glycoprotein-mediated drug resistance by hsp90 beta. Anticancer Drugs 7:838–845
Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198–1206
Conflict of interest statement
The authors declare that they have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kabakov, A.E., Kudryavtsev, V.A. & Gabai, V.L. Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 88, 241–247 (2010). https://doi.org/10.1007/s00109-009-0562-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-009-0562-0